NCT02033252

Brief Summary

This randomized controlled study aimed to evaluate the efficacy and safety of acupuncture therapy on persistent allergic rhinitis patients complicated with asthma.

Trial Health

55
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
30

participants targeted

Target at below P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2014

Completed
6 days until next milestone

First Submitted

Initial submission to the registry

January 7, 2014

Completed
3 days until next milestone

First Posted

Study publicly available on registry

January 10, 2014

Completed
1.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2015

Completed
Last Updated

September 2, 2015

Status Verified

August 1, 2015

Enrollment Period

1.9 years

First QC Date

January 7, 2014

Last Update Submit

August 31, 2015

Conditions

Outcome Measures

Primary Outcomes (1)

  • Total Nasal Symptom Score (TNSS)

    Change from Baseline TNSS Score at 4 Weeks after Randomization

Secondary Outcomes (6)

  • Rhinitis Quality of Life Questionnaire (RQLQ)

    Change from Baseline at 2 Weeks after Randomization (Both Groups), Change from Baseline at 4 Weeks after Randomization (Both Groups), Change from Baseline at 8 Weeks after Randomization (Active Group Only)

  • Quality of Life Questionnaire for adult Korean Asthmatics (QLQAKA)

    Change from Baseline at 2 Weeks after Randomization (Both Groups), Change from Baseline at 4 Weeks after Randomization (Both Groups), Change from Baseline at 8 Weeks after Randomization (Active Group Only)

  • Visual Analogue Scale

    Change from Baseline at 2 Weeks after Randomization (Both Groups), Change from Baseline at 4 Weeks after Randomization (Both Groups), Change from Baseline at 8 Weeks after Randomization (Active Group Only)

  • Pulmonary function test (PFT)

    Baseline, four weeks after randomization (both groups)

  • Euro Quality of Life-5 Dimention Questionnaire (EQ-5D)

    Baseline, four weeks after randomization

  • +1 more secondary outcomes

Study Arms (2)

Acupuncture

EXPERIMENTAL

A series of acupuncture sessions within four weeks from the baseline with concurrent conventional medications for asthma

Device: Acupuncture

Waiting

NO INTERVENTION

Participants who will be allocated to waitlist will receive no acupuncture treatments throughout the 4 weeks while receiving other conventional managements for asthma. After 4 weeks, if participants choose to try the acupuncture treatment, the active acupuncture treatment will be provided for 4 weeks (3 sessions/week).

Interventions

In the acupuncture treatment group, 10 acupuncture points (bilateral LI4, TE23, ST36, unilateral EHN-1, GV23, LI20 and LI4) will be inserted with 0.20 mm in diameter x 30 mm in length disposal needles. The needle will be inserted to a depth of 10 - 30 mm, according to the points selected. The participating acupuncture doctors will manually manipulate the acupuncture needles with de-qi sensation and maintain the needles for 10 minutes with two times of manual stimulation, at the beginning and at the end.

Acupuncture

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Suffering from persistent Allergic rhinitis (PAR; nasal obstruction, rhinorrhoea, sneezing and nasal itching) symptoms for more than 4 days/week, and greater than 4 consecutive weeks.
  • Moderate-severe symptoms according to Allergic rhinitis and its impact on asthma (ARIA) criteria.
  • Positive reaction for more than or equal to one respiratory allergen (SPT or MAST)
  • Stable asthma symptoms with diagnosis of Asthma by respiratory or allergic disease specialist.
  • No changes in asthma or allergic rhinitis drugs for the past month
  • Aged greater than or equal to 18 years, either sex.
  • No problem with expression of opinion
  • Provided with written consent
  • No other disease except allergic rhinitis or asthma which could affect the disease.

You may not qualify if:

  • Having experience using ventilator due to exacerbation of asthma symptoms within six months.
  • Experience of acute respiratory tract infection treated with antibiotics within 14 days
  • Having anatomical occlusion or deformation in nasal cavity.
  • Signs of infection in chest X-ray or having active respiratory disease except asthma
  • Below or equal to 4 on Total nasal symptom score (TNSS) in the latest week.
  • Received drugs affecting directly to allergic rhinitis such as H1-antihistamines, decongestants (nasal, oral or ocular), corticosteroids within 14 days.
  • Received following treatments for allergic rhinitis or asthma within six months ; Traditional Korean medicine interventions such as acupuncture, moxibustion, cupping therapy and herbal medication inhalation or CAM including homeopathy.
  • Received herbal medication for allergic rhinitis or asthma within 14 days.
  • Pregnant, planning the pregnancy or breast-feeding
  • Tuberculosis, hepatitis or more than 2 x normal limit of serum creatinine, aspartate aminotransferase/alanine aminotransferase (AST/ALT).
  • Skin lesion on acupoint or other systemic disease insufficient for acupuncture.
  • Night-shift workers staying up all night
  • Who cannot participate clinical trial properly.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

National Clinical Research Center, Korean Medicine Hospital, Pusan National University

Yangsan, Kyungsangnamdo, 626-770, South Korea

RECRUITING

MeSH Terms

Conditions

Rhinitis, AllergicAsthma

Interventions

Acupuncture Therapy

Condition Hierarchy (Ancestors)

RhinitisNose DiseasesRespiratory Tract DiseasesRespiratory HypersensitivityOtorhinolaryngologic DiseasesHypersensitivity, ImmediateHypersensitivityImmune System DiseasesBronchial DiseasesLung Diseases, ObstructiveLung Diseases

Intervention Hierarchy (Ancestors)

Complementary TherapiesTherapeutics

Study Officials

  • Jun-Yong Choi, KMD, PhD

    Korean Medicine Hospital, Pusan National University

    PRINCIPAL INVESTIGATOR
  • Yun Seong Kim, MD, PhD

    Yangsan Pusan National University Hospital

    PRINCIPAL INVESTIGATOR
  • Seung Eun Lee, MD

    Yangsan Pusan National University Hospital

    STUDY DIRECTOR

Central Study Contacts

Minjoo Kang, BcS

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Assistant Professor

Study Record Dates

First Submitted

January 7, 2014

First Posted

January 10, 2014

Study Start

January 1, 2014

Primary Completion

December 1, 2015

Last Updated

September 2, 2015

Record last verified: 2015-08

Locations